Oculis Holding AG (OCS) Restructuring Costs (2023)
Oculis Holding AG's (OCS) quarterly Restructuring Costs came in at -$71325.6 in Q3 2023, up 97.33% quarter-over-quarter from -$2.7 million in Q2 2023.
Oculis Holding AG (OCS) Restructuring Costs (2023) Analysis & Trends
Oculis Holding AG's Restructuring Costs history runs 1 years deep, the most recent figure standing at -$71325.6 for Q3 2023.
- On a quarterly basis, Restructuring Costs changed N/A year-over-year to -$71325.6 in Q3 2023; TTM through Dec 2023 was -$5.1 million, a N/A change from a year earlier, with the FY2023 full-year figure at -$5.1 million, down 2186.62% from the prior year.
- Restructuring Costs rose to -$71325.6 in Q3 2023 per OCS's latest filing, from -$2.7 million in the prior quarter.
- Across five years, Restructuring Costs topped out at -$71325.6 in Q3 2023 and bottomed at -$2.7 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -71,325.61 |
| Jun 30, 2023 | -2.67 Mn |
| Mar 31, 2023 | -2.31 Mn |